secukinumab
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Axial Spondyloarthritis
Conditions
Axial Spondyloarthritis, Psoriatic Arthritis
Trial Timeline
Jun 2, 2021 → Dec 31, 2021
NCT ID
NCT05677542About secukinumab
secukinumab is a pre-clinical stage product being developed by Novartis for Axial Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT05677542. Target conditions include Axial Spondyloarthritis, Psoriatic Arthritis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05583604 | Pre-clinical | Active |
| NCT07243782 | Pre-clinical | Recruiting |
| NCT06751238 | Phase 1 | Recruiting |
| NCT06905288 | Pre-clinical | Recruiting |
| NCT06331312 | Phase 3 | Recruiting |
| NCT06130540 | Phase 1 | Completed |
| NCT05569174 | Phase 3 | Completed |
| NCT05232864 | Phase 3 | Terminated |
| NCT05206591 | Phase 3 | Withdrawn |
| NCT04894890 | Pre-clinical | Completed |
| NCT04717466 | Approved | Completed |
| NCT05677542 | Pre-clinical | Completed |
| NCT05513014 | Pre-clinical | Completed |
| NCT05320159 | Pre-clinical | Completed |
| NCT05650060 | Pre-clinical | Completed |
| NCT03866317 | Phase 2 | Withdrawn |
| NCT03769168 | Phase 3 | Completed |
| NCT03791060 | Phase 2 | Terminated |
| NCT03440736 | Approved | Completed |
| NCT03307447 | Approved | UNKNOWN |
Competing Products
20 competing products in Axial Spondyloarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 52 |
| Brodalumab + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR-1314 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Upadacitinib | AbbVie | Pre-clinical | 23 |
| Adalimumab | AbbVie | Approved | 85 |
| Adalimumab + Placebo + Open-label Adalimumab | AbbVie | Phase 3 | 77 |
| adalimumab + Placebo | AbbVie | Phase 3 | 77 |
| Treatment | Merck | Pre-clinical | 23 |
| Golimumab | Merck | Phase 3 | 77 |
| Tulisokibart + Placebo | Merck | Phase 2 | 52 |
| Secukinumab 150 milligram [Cosentyx] | Novartis | Approved | 85 |
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |
| Secukinumab + Placebo + Secukinumab | Novartis | Approved | 85 |
| Secukinumab + Secukinumab and Placebo | Novartis | Phase 3 | 77 |
| Secukinumab/Adalimumab-Biosimilar | Novartis | Phase 3 | 77 |
| Brodalumab 210 mg + Placebo | Amgen | Phase 2 | 51 |
| Etanercept 25mg + Sulfasalazine | Pfizer | Phase 2 | 51 |